...
首页> 外文期刊>Pharmaceutical Chemistry Journal >Evaluation of Cytotoxic Activity of New Benzimidazole-Piperazine Hybrids Against Human MCF-7 and A549 Cancer Cells
【24h】

Evaluation of Cytotoxic Activity of New Benzimidazole-Piperazine Hybrids Against Human MCF-7 and A549 Cancer Cells

机译:对人MCF-7和A549癌细胞对新苯并咪唑 - 哌嗪杂交种细胞毒性活性的评价

获取原文
获取原文并翻译 | 示例

摘要

A series of benzimidazole-piperazine hybrids (14 - 37) were designed, synthesized and evaluated for their cytotoxic activity against human lung (A549) and breast (MCF-7) cancer cell lines. Preliminary evaluation revealed that most of these hybrid molecules (i.e., 16 - 25) exhibited noteworthy and preferential antiproliferative effect against human lung cancer (A549) with IC50 values of 2.8 - 7.8 mu M. Among the synthesized molecules, compound 17 showed the most balanced cytotoxic effect against lung (A549) and breast (MCF-7) cancer cells with IC50 values of 5.4 and 4.2 mu M, respectively. To explore the mechanistic aspects fundamental to the observed activity, further biological studies of compounds 16, 17 and 22 were carried out. In addition, these compounds induced PARP-1 cleavage and caspase 7 activation, caused morphological changes such as bleb formation in the treated cells, and significantly increased the nuclear fragmentation. Taken all together, our findings indicate that cytotoxic activities of newly synthesized benzimidazole-piperazine hybrids are mediated through the apoptotic cell death induction. These benzimidazole derivatives have the potential for further development as anticancer agents.
机译:设计了一系列苯并咪唑 - 哌嗪杂交物(14-37),用于对人肺(A549)和乳腺(MCF-7)癌细胞系的细胞毒性活性。初步评价显示,大多数这些杂化分子(即,16-25)对人肺癌(A549)表现出不值得注意的抗增殖作用(A549),IC 50值为2.8-7.8μm。在合成的分子中,化合物17显示出最平衡的对肺(A549)和乳腺(MCF-7)癌细胞的细胞毒性效应分别具有5.4和4.2μm的IC 50值。为了探讨机械方面对观察到的活性的基础,进行了化合物16,17和22的进一步生物学研究。此外,这些化合物诱导PARP-1裂解和胱天蛋白酶7活化,使得在经处理的细胞中导致诸如BLEB形成的形态变化,并显着增加了核碎裂。我们的研究结果表明,新合成的苯并咪唑 - 哌嗪杂交物的细胞毒性活性通过凋亡细胞死亡诱导介导。这些苯并咪唑衍生物具有进一步发展作为抗癌剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号